Russell Skibsted
Known title: Chief Financial OfficerCIK: 0001308105
Russell Skibsted's purchase track record
Russell Skibsted has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/30/2026 | PCSA | $6K | -8.3% | pending | — |
| 6/15/2026 | PCSA | $6K | -14.0% | pending | — |
| 5/29/2026 | PCSA | $6K | -19.1% | pending | — |
| 5/15/2026 | PCSA | $6K | -17.9% | pending | — |
| 4/30/2026 | PCSA | $6K | -24.4% | pending | — |
| 4/15/2026 | PCSA | $6K | -19.3% | -45.4% | +9.9% |
| 3/31/2026 | PCSA | $6K | -24.0% | -30.3% | +17.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PCSA | ▲ Buy | Open Market | 3,277 | $6K | 6/30/2026 | View on chart |
| PCSA | ▲ Buy | Open Market | 2,654 | $6K | 6/15/2026 | View on chart |
| PCSA | ▲ Buy | Open Market | 2,292 | $6K | 5/29/2026 | View on chart |
| PCSA | ▲ Buy | Open Market | 1,984 | $6K | 5/15/2026 | View on chart |
| PCSA | ▲ Buy | Open Market | 2,190 | $6K | 4/30/2026 | View on chart |
| PCSA | ▲ Buy | Open Market | 1,984 | $6K | 4/15/2026 | View on chart |
| PCSA | ▲ Buy | Open Market | 2,324 | $6K | 3/31/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Processa Files Prospectus for 306.5M Share Offering
Processa Pharmaceuticals filed a prospectus for an offering of 306.574 million common shares on behalf of selling shareholders. This large-scale secondary offering adds significant supply to the market, which may pressure the stock price. The company is currently trading near the lower end of its 52-week range, with technical indicators showing weakness.
Processa Files Prospectus for 306.5M Share Offering. Processa Pharmaceuticals filed a prospectus for an offering of 306.574 million common shares on behalf of selling shareholders. This large-scale secondary offering adds significant supply to the market, which may pressure the stock price. The company is currently trading near the lower end of its 52-week range, with technical indicators showing weakness.